斯莱普泰

Slaiputai is a Beijing-based biotechnology company specializing in the research, development, and industrialization of peptide-based therapeutics. The company leverages its proprietary peptide technology platform to focus on metabolic diseases, particularly targeting the glucagon-like peptide-1 (GLP-1) receptor for indications such as type 2 diabetes and obesity. Slaiputai's pipeline includes several long-acting peptide candidates, including dual and triple agonists, designed to improve patient compliance and therapeutic efficacy. The company is currently advancing its lead candidate, SLP-01, through clinical trials while expanding its portfolio into other metabolic and endocrine disorders. Slaiputai aims to provide high-quality, affordable peptide drugs to the global market through its integrated R&D and manufacturing capabilities.